FTUCX
Price
$52.82
Change
+$0.21 (+0.40%)
Updated
Sep 20 closing price
TTMIX
Price
$151.75
Change
+$0.04 (+0.03%)
Updated
Sep 20 closing price
Ad is loading...

FTUCX vs TTMIX

Header iconFTUCX vs TTMIX Comparison
Open Charts FTUCX vs TTMIXBanner chart's image
Fidelity Advisor Telecommunications C
Price$52.82
Change+$0.21 (+0.40%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Comm & Tech I
Price$151.75
Change+$0.04 (+0.03%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
FTUCX vs TTMIX Comparison Chart
Loading...
VS
FTUCX vs. TTMIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FTUCX is a StrongBuy and TTMIX is a Buy.

FUNDAMENTALS
Fundamentals
TTMIX has more cash in the bank: 9.07B vs. FTUCX (196M). FTUCX pays higher dividends than TTMIX: FTUCX (1.66) vs TTMIX (0.24). FTUCX was incepted earlier than TTMIX: FTUCX (18 years) vs TTMIX (9 years). TTMIX is a more actively managed with annual turnover of: 33.90 vs. FTUCX (24.00). FTUCX has a lower initial minimum investment than TTMIX: FTUCX (0) vs TTMIX (500000). TTMIX (27.64) and FTUCX (26.58) have marching annual gain over last year. TTMIX return over 5 years is better than : 25.53 vs. FTUCX (-7.79).
FTUCXTTMIXFTUCX / TTMIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence18 years9 years-
Gain YTD16.47523.85469%
Front LoadN/AN/A-
Min. Initial Investment0500000-
Min. Initial Investment IRA500N/A-
Net Assets196M9.07B2%
Annual Yield % from dividends1.660.24702%
Returns for 1 year26.5827.6496%
Returns for 3 years-18.26-29.7161%
Returns for 5 years-7.7925.53-31%
Returns for 10 years-9.32N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MSB21.240.40
+1.92%
Mesabi Trust
ALKS27.830.09
+0.32%
Alkermes plc
KVUE23.19-0.20
-0.86%
Kenvue
AGX88.39-0.80
-0.90%
Argan
QNCX0.74-0.02
-2.65%
Quince Therapeutics